Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Kalvista Pharmaceuticals Limited has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners. The prosecution is centralized within 1 distinct art unit.
Busiest examiner COHEN, MICHAEL P is responsible for 1 pending office action. The use of a single art unit for both pending actions may lead to similar prior art being cited across the portfolio. Practitioners should monitor the 1 art unit closely for any shifts in examination policy that could affect both cases. While 2 distinct examiners are involved, the shared technical space of the single art unit provides a common ground for prosecution. This structure ensures that the 2 pending office actions are subject to the same overarching administrative standards, even if the individual examiners have different personal styles.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COHEN, MICHAEL P | 1 | 58.7% | +27.5% |
| THOMAS, TIMOTHY P | 1 | 26.3% | +38.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17633973 | ENZYME INHIBITORS | THOMAS, TIMOTHY P | 24d overdue |
| 18859650 | FORMULATIONS OF A PLASMA KALLIKREIN INHIBITOR | COHEN, MICHAEL P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17633973 | ENZYME INHIBITORS | THOMAS, TIMOTHY P | 24d overdue |
| 18859650 | FORMULATIONS OF A PLASMA KALLIKREIN INHIBITOR | COHEN, MICHAEL P | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18859650 | FORMULATIONS OF A PLASMA KALLIKREIN INHIBITOR | COHEN, MICHAEL P | — | §102§103§112Other | Non-Final OA | — | Pending | Oct 24, 2024 |
| 17633973 | ENZYME INHIBITORS | THOMAS, TIMOTHY P | 1614 | §102§112 | Non-Final OA | 24d overdue | Pending | Feb 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial